Evidence mapPaperPMID 39826010Full record

ReviewBiotechnology letters2025

Clinical and mechanistic insights into biomedical application of Se-enriched probiotics and biogenic selenium nanoparticles.

Farshid Ataollahi, Bagher Amirheidari, Zohreh Amirheidari, Mahshid Ataollahi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Biotechnology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Multi-enzyme mimic MnRSC advances · 2026
    Article
  2. Organic and inorganic selenium-enrichedFrontiers in nutrition · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Farshid AtaollahiExtremophile and Productive Microorganisms Research Center, Kerman University of Medical Sciences, Kerman, Iran.
Bagher AmirheidariPharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran. b.amirheidari@kmu.ac.ir.ORCID http://orcid.org/0000-0003-1086-4286
Zohreh AmirheidariExtremophile and Productive Microorganisms Research Center, Kerman University of Medical Sciences, Kerman, Iran.
Mahshid AtaollahiExtremophile and Productive Microorganisms Research Center, Kerman University of Medical Sciences, Kerman, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Selenium is an essential element with various industrial and medical applications, hence the current considerable attention towards the genesis and utilization of SeNPs. SeNPs and other nanoparticles could be achieved via physical and chemical methods, but these methods would not only require expensive equipment and specific reagents but are also not always environment friendly. Biogenesis of SeNPs could therefore be considered as a less troublesome alternative, which opens an excellent window to the selenium and nanoparticles' world. bSeNPs have proved to exert higher bioavailability, lower toxicity, and broader utility as compared to their non-bio counterparts. Many researchers have reported promising features of bSeNP such as anti-oxidant and anti-inflammatory, in vitro and in vivo. Considering this, bSeNPs have been tried as effective agents for health disorders, especially as constituents of probiotics. This article briefly reviews selenium, selenium nanoparticles, Se-enriched probiotics, and bSeNPs' usage in an array of health disorders. Obviously, there are very many articles on bSeNPs, but we wanted to summarize studies on prominent bSeNPs features published in the twenty-first century. This review is hoped to give an outlook to researchers for their future investigations, ultimately serving better care of health disorders.

Indexed as

NanoparticlesProbioticsSeleniumAnimalsAnti-Inflammatory AgentsAntioxidantsHumansAnti-Inflammatory AgentsAntioxidantsSeleniumAnti-oxidantBiogenicCancerLactobacillusNanoparticleSe-enrichedSelenium

Identifiers

PMID39826010

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.